Shanghai-based Alpha Biopharma announced the completion of the last patient visit in the Phase II/III EVEREST study for its next-generation EGFR inhibitor zorifertinib, targeting EGFR mutation-positive non-small cell lung cancer (NSCLC) patients with central nervous system (CNS) metastases. Topline data is expected by the end of 2022.
Study Details
The multi-regional clinical trial (MRCT) enrolled 492 patients across mainland China, Taiwan, South Korea, and Singapore. Led by Professor Wu Yilong, the study demonstrated zorifertinib’s high blood-brain barrier (BBB) penetration and efficacy in metastatic CNS lesions, with a safety profile comparable to other EGFR-TKIs.
Company Background
Founded in 2017, Alpha Biopharma developed zorifertinib, an oral reversible EGFR-TKI targeting L858R and Exon19Del mutations. The firm’s pipeline also includes an NK cell therapy for acute myeloid leukemia and a CAR-T cell therapy licensed from Wugen Inc. for Greater China.-Fineline Info & Tech
